InterCure Ltd. INCR
3.97 USD -0.08 (-1.98%)
Nov 3, 2026, 3:56 PM EST
3.99 Day range 4.11
3.40 52-week range 7.55
- YTD
- -12.75%
- 1 year
- -45.62%
- Market cap
- 59.56M
- Revenue (ttm)
- 272.67M
- Profit margin
- -24.07%
- EPS (ttm)
- -0.95
- Shares out
- 45.77M
- Forward P/E
- -1.21
- YTD return
- -12.75%
- 1-year return
- -45.62%
- Volume
- 2.48K
- Avg volume
- 22.35K
- Open
- 4.09
- Previous close
- 4.05
- Day's range
- 3.99 – 4.11
- 52-week range
- 3.40 – 7.55
- Beta
- 0.03
6M -0.02 (-0.49%)
Key statistics
- Enterprise value
- 203.36M
- PEG ratio
- 0.00
- Price / sales
- 0.30
- Price / book
- 0.19
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -38.60%
- Free cash flow
- 0
- Total cash
- 20.30M
- Total debt
- 150.81M
- Return on equity
- -13.61%
- Short % of float
- 0.15%
- 50-day average
- 1.52
- 200-day average
- 2.14
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
INCR Revenue — quarterly 102.44M
INCR Net income — quarterly 4.88M
INCR EPS — quarterly 0.525
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 31, 2023 | Jun 1, 2023 | 0.00 | 0.03 | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | 0.00 | — | — |
| Mar 31, 2023 | Dec 1, 2022 | 0.00 | 0.05 | — | — |
| Nov 15, 2022 | Sep 1, 2022 | 0.00 | 0.05 | — | — |
| Aug 15, 2022 | Jun 1, 2022 | 0.00 | 0.10 | — | — |
| May 16, 2022 | Mar 1, 2022 | 0.00 | 0.11 | — | — |
About InterCure Ltd.
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Israel
- Website
- intercure.co
News
Comparing Tilray Brands (NASDAQ:TLRY) and InterCure (NASDAQ:INCR) 
InterCure Regains Nasdaq Compliance 
InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement 
InterCure (NASDAQ:INCR) & Silo Pharma (NASDAQ:SILO) Financial Review 
InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages 
InterCure Enters Private Placement With Its CEO And Other Shareholders For Commitments Of ~$7.4M, With Option To Increase To ~$18.6M 
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds 
InterCure Reports Growing Demand In Germany And Evaluates Opportunities In Regulated U.S. Medical Cannabis Markets 
InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition 
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
Your note
Sign in to keep a note on INCR — it syncs with the Stock Master app.